Post-exposure prophylaxis (PEP): A practical guide

Adele Visser MBChB
Senior Registrar Department Clinical Pathology, University of Pretoria, National Health Laboratory Service, Tshwane Academic Division

Hilgaard F Visser MBChB
Senior Registrar Department Orthopaedic Surgery, University of Pretoria

Karin L Richter MMed(Path-Viro), FCS(Path-Viro). Dip HIV Man, Dip Obs&G
Consultant and Lecturer Department Medical Virology, University of Pretoria, National Health Laboratory Service, Tshwane Academic Division

Reprint requests:
Dr A Visser
Private Bag X1 Suite 22
Queenwood
Pretoria
0121
Contact number: (012) 780-1051
Fax number: (012) 329-7777
Email: adele@up.ac.za

Introduction
Occupational exposure to blood-borne pathogens pose a major threat to health care workers (HCWs), with more than half a million reported cases annually in the USA alone.1 South African statistics are limited, but small studies show exposure rates varying from 48% in medical students2 to 54% among ward staff (including doctors, nurses and support staff)3, to as high as 91% among junior doctors.1 Of some concern is the fact that over 60% of these incidents are not reported,1 with a higher rate of not reporting exposure among those with a greater number of exposures.4 Risks involved in exposures are summarised in Table I.

Table I: Transmission risk in the South African setting

<table>
<thead>
<tr>
<th>South African sero-prevalence without</th>
<th>Transmission risk prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBV 5-18%6</td>
<td>HBsAg positive 6-10%7</td>
</tr>
<tr>
<td>HBeAg positive 30-33%7</td>
<td></td>
</tr>
<tr>
<td>HCV 2.0-2.9%4</td>
<td>3%7</td>
</tr>
<tr>
<td>HIV-1 17.64%6</td>
<td>0.3%7</td>
</tr>
</tbody>
</table>

HBV – Hepatitis B Virus
HCV – Hepatitis C Virus
HIV-1 – Human immunodeficiency virus 1

Exposure prevention
The most important step in ensuring the safety of HCWs is by prevention of exposure. This is the responsibility of both the employer and the employee. Standard precautions should be practised at all times where contact with infectious body fluids occurs, and safety should be ensured by the ample availability of equipment ensuring safety (including sharps-containers, protective wear, etc.) Included in prevention strategies is vaccination against HBV of all HCWs exposed to possible infectious material.

The most important step in ensuring the safety of HCWs is by prevention of exposure.
An antibody level more than 10 IU/ml is considered to be protective, should an exposure occur. There are currently three vaccines which contain Hepatitis B virus recombinant-DNA surface antigen available in South Africa, namely Energix-B (GlaxoSmithKline Biologicals), HeberBiovac (Biovac) and, in combination with Hepatitis A vaccine, Twinrix (GlaxoSmithKline Biologicals). Should the immune response following vaccination be inadequate (antibody level <10 IU/ml), a modified revaccination approach should be followed to possibly still induce immunity (see Figure 1). Risk factors for non-response include:

- age older than 30 years
- obesity
- immunodeficiency

For management of a true non-responder after an exposure refer to Table IV.

What constitutes an exposure?
The following should be regarded as infectious material:

- blood or blood-stained tissue, fluid or material
- sexual fluids
- tissue fluids (including cerebrospinal fluid, pleural fluid, effusions, wound secretions, etc.)

If there is no contamination with the above-mentioned fluids, the following may be regarded as non-infectious:

- sweat
- tears
- saliva and sputum
- urine
- stool

Management of wound site
Percutaneous injuries
The exposure site should be washed thoroughly with soap and water. No evidence exists that expressing fluid by squeezing or inducing bleeding reduces the risk of blood-borne pathogen transmission. Avoid too intense a massage or contusions. Use of antiseptics on the wound site has not been shown to reduce transmission risk, but use is not contraindicated. Use of caustic agents like bleach, and injection of antiseptics into the wound site is not recommended.

Mucous membrane exposures
The exposed mucous membrane should be flushed with water.

Initial special investigations
Baseline testing should be performed to determine management as well as for administrative reasons. Most laboratories have protocols available, and would be able to supply this information on request. The following tests are recommended in the latest Southern African HIV Clinicians Society Guidelines, published in 2008.

Patient (or source of exposure):
- HIV-1 serology
- Hepatitis B surface antigen
- Hepatitis C serology

Health care worker (or exposed person):
- HIV-1 serology
- Hepatitis B surface antibodies
- Hepatitis C serology

Additional testing:
- Full blood count with differential count
- UKE (if Tenofovir is used as part of prophylaxis)
- AST and ALT
- Glucose (if a protease inhibitor is used as part of prophylaxis)

HIV-1 risk determination
The risk of transmission of HIV-1 during an exposure is determined by various factors and should be assessed as stated in Table II.
In cases where the status of the source patient is unknown and/or cannot be determined, the source should be regarded as at high risk for infection with HIV and HBV. In patients testing HIV negative the following should be considered:

- **The ‘window period’ for HIV is defined as the time from infection with HIV to actual seroconversion. The implication is that during this period, the patient’s body fluids will be highly infectious, despite a negative HIV serology. Other HIV tests, including HIV-1 DNA and RNA PCR will also be negative in this early stage. Using a 4th generation ELISA (testing for both anti-HIV antibodies and the p24 antigen), the window period is shortened to a minimum of 18 days.**

- **If the source patient is known to engage in high risk activities (unprotected sexual practices, intravenous drug use, etc.), PEP may be indicated.**

### Timing and duration of PEP

PEP should be initiated as soon as possible; efficacy after 72 hours is unlikely. All PEP regimens should be taken for the full 28 days, as animal studies have proven greatest efficacy for this time period, with limited additional benefit after 4 weeks. Compliance is a big issue and in small studies, PEP default has been as high as 33%, and side effects can occur in up to 50% of cases. Although controversial, there have been case reports where the protease inhibitor was stopped following side-effects, with completion of a two-drug regimen.

### Antiretroviral choice

The choice as to which antiretroviral to use should be based on availability, local guidelines, side-effect profile and dosing schedule. Drug regimens are summarised in Table III, as adapted from reference 1.

#### Expert consultation

There are various situations where the choice of drugs to use in the PEP regimens is best discussed with an expert in the field, as in the following:

- resistance (or possible resistance) of the source virus to antiretroviral agents
- co-morbid disease, pregnancy or possibility of adverse drug interactions in the exposed
- toxicity to the initial PEP regimen

#### Hepatitis B risk determination

Of the three viruses discussed, Hepatitis B is the most highly transmissible, and yet preventable by adequate immunisation. Upon exposure, the HCW’s immune status should be evaluated. Any titre above 10 IU/ml is considered adequate for protection. Management is outlined in Table IV:

---

**Table II:**

<table>
<thead>
<tr>
<th>INJURY FACTORS</th>
<th>PATIENT FACTORS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HIV negative</td>
</tr>
<tr>
<td></td>
<td>No PEP indicated unless high risk patient</td>
</tr>
<tr>
<td></td>
<td>No PEP indicated unless high risk patient</td>
</tr>
</tbody>
</table>

---

**Table III:**

<table>
<thead>
<tr>
<th>Drug regimens available for PEP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Two drug regimen</strong></td>
</tr>
<tr>
<td><strong>Once a day regimen</strong></td>
</tr>
<tr>
<td>• Tenofovir + Emtricitabine</td>
</tr>
<tr>
<td>(Truvada®)</td>
</tr>
<tr>
<td><strong>Lopinavir/ritonavir 800/200</strong></td>
</tr>
<tr>
<td>(Aluvia®)</td>
</tr>
<tr>
<td><strong>Twice a day regimen</strong></td>
</tr>
<tr>
<td>• Stavudine + Lamivudine</td>
</tr>
<tr>
<td>(Truvada®)</td>
</tr>
</tbody>
</table>

* Stavudine is well tolerated in PEP due to the short duration of use.
* AZT is very poorly tolerated in PEP owing to various side-effects. However, it is the drug with the most available data regarding its use in PEP.
* Efavirenz should be used with precaution in patients with pre-existing psychiatric illness, and is contraindicated in pregnancy.
If the source status is unknown or unavailable for testing, it should be assumed that the person is HBV positive, and should be managed accordingly. If Hepatitis B immunoglobulin is indicated, it should be administered preferably within 24 hours of exposure. Efficacy after seven days is unlikely.

If the HCW is an established non-responder they should receive two doses of HBIg, one dose as soon as possible after exposure, and the second dose 1 month later.

Hepatitis C risk determination
The actual risk of contracting Hepatitis C upon exposure within the South African context is quite low, if one takes into consideration both the low seroprevalence rate (2.0-2.9%) and the low transmission rate (3.0%).

Exposure to body fluids from a HCV infected patient does not warrant immunoglobulin or antiviral administration. Serial monitoring of the HCW should be performed, and should seroconversion occur, the person should be referred to a specialist in the field early during the course of the disease.

Follow-up monitoring
Testing at two weeks post-exposure specifically focuses on monitoring for toxicity. If toxicity or side-effects occur, the regimen should be altered to facilitate completion of the 28-day PEP. Subsequent testing is for medico-legal documentation and early management (Table V).

Common pitfalls and misconceptions
• If a patient is HIV negative, an exposed HCW has no risk of contracting HIV.
  ◦ A patient can still be in the window period after HIV exposure with a non-reactive HIV serology test, but high HIV-1 viral load and thus highly infectious.
  ◦ A negative HIV-1 DNA PCR result in HCW while taking PEP can shorten the duration of PEP.
  ◦ In all cases, a full 28-day course is advised since this has been shown to confer the most effective protection from viral transmission.
  ◦ A negative HIV-1 DNA PCR after completion of PEP make further follow-up testing unnecessary.
  ◦ Despite the fact that an HIV-1 DNA PCR is a specific test, it still has a lower limit of detection. This implies that a false negative can be obtained if a small number of cells actually harbour viral nucleic acid. The appropriate follow-up with HIV-serology is still advised at 6 weeks, 3 months and 6 months following exposure.

Helpful references and contacts
• Toll-free national HIV health care worker hotline (Mondays to Fridays 8.30am – 4.30pm): Tel: 0800 212506.

Table IV:
Recommended PEP for exposure to Hepatitis B virus

<table>
<thead>
<tr>
<th>SOURCE</th>
<th>HBsAg positive</th>
<th>HBsAg negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unvaccinated</td>
<td>HBIg*</td>
<td>Start vaccination</td>
</tr>
<tr>
<td>Vaccinated Responder HBsAb&gt;10 IU/ml</td>
<td>No treatment</td>
<td>No treatment</td>
</tr>
<tr>
<td>Vaccinated Non-Responder HBsAb&gt;10 IU/ml</td>
<td>HBIg*</td>
<td>Start revaccination</td>
</tr>
</tbody>
</table>

* HBIg – Hepatitis B virus immunoglobulin

Table V:
Timing of bloods during PEP

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>2 weeks</th>
<th>6 weeks</th>
<th>3 months</th>
<th>6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>HBV</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCV</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FBC &amp; differential</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AST/ALT</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UKE</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Occupational exposure

Take first dose of PEP

Provide immediate care to the exposure site

Evaluate the source:
- Obtain informed consent and perform:
  - HIV-serology
  - Hepatitis B surface antigen
  - Hepatitis C serology

Evaluate the exposed person:
- Baseline testing (at Casualties)
  - HIV-serology
  - Hepatitis B surface antibodies
  - Hepatitis C serology
  - FBC and differential
  - AST and ALT
  - UKE
  - Glucose
- Determine HBV immune status
  - HBsAb > 10 IU/ml considered protective

<table>
<thead>
<tr>
<th>Exposure type</th>
<th>HIV positive</th>
<th>HIV positive</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low risk</td>
<td>High risk</td>
</tr>
<tr>
<td>Solid needle</td>
<td>3 Drug PEP</td>
<td>3 Drug PEP</td>
</tr>
<tr>
<td>Small volume</td>
<td></td>
<td></td>
</tr>
<tr>
<td>splash</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hollow needle</td>
<td>3 Drug PEP</td>
<td>3 Drug PEP</td>
</tr>
<tr>
<td>Deep puncture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visible blood</td>
<td></td>
<td></td>
</tr>
<tr>
<td>on needle</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Needle used</td>
<td></td>
<td></td>
</tr>
<tr>
<td>in venepuncture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major splash</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vaccination response</th>
<th>Source HBsAg positive</th>
<th>Source HBsAg negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unvaccinated</td>
<td>HBsAg x1 and start vaccination</td>
<td>HBV vaccination</td>
</tr>
<tr>
<td>Vaccinated and known responder</td>
<td>No treatment</td>
<td>No treatment</td>
</tr>
<tr>
<td>Vaccinated and known non-responder</td>
<td>HBsAg x2</td>
<td>No treatment</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>2 weeks</th>
<th>6 weeks</th>
<th>3 months</th>
<th>6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV serology</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>HBV</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCV</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FBC &amp; diff</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UKE</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AST &amp; ALT</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 2:
Summary on PEP in a health care worker

Also see: CDC. Notice to Readers: Updated Information Regarding Antiretroviral Agents Used as HIV Post exposure Prophylaxis for Occupational HIV Exposures. MMWR 2007;56(49):1291-2
Available from: http://www.cdc.gov/mmwr/pre-view/mmwrhtml/mm5649a4.htm


Summary on practical management of PEP
This is the current protocol implemented at the Department of Orthopaedics, University of Pretoria (see also Figure 2).

Upon exposure:
1. Wash the wound site or irrigate mucous membrane exposures as described above.
2. Take the first dose of PEP from the starter pack which should be readily available. Taking PEP can always be stopped later if not indicated.

_It is current practice at the Department of Orthopaedics, University of Pretoria to keep PEP drugs available to its personnel. Upon exposure, they have immediate access to these drugs and can therefore complete any administrative procedures as time permits. It is emphasised however, that the appropriate channels should be followed to ensure proper legal liability from the hospital._

3. Obtain consent from your patient and take the appropriate bloods from both the patient and the HCW. Most laboratories should have a protocol in place on which special investigations are indicated, based on the South African PEP guidelines. It is therefore possible to contact your local laboratory and ask for the appropriate test names as indicated in both the injured and patient.

4. Report the incident to the authorities tasked with handling these incidents and finish the necessary paperwork, e.g. ‘Injury on Duty’ forms.

5. Follow up on Hepatitis B immune status and follow up blood investigations as indicated.

6. Monitor for side-effects – if severe, consider converting to two-drug regimen, to ensure completion of PEP.

The content of this article is the sole work of the authors. No benefits of any form have been derived from any commercial party related directly or indirectly to the subject of this article.

**References**


